YolTech has received FDA approval for its investigational new drug (IND) application for YOLT-101 to treat HeFH.

In this article, GlobalData examines key reimbursement trends that reflect the current delays to patient access across the ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

Aytu BioPharma has signed an agreement with Fabre-Kramer Pharmaceuticals to commercialise Exxua in the US market for MDD.

Vividion Therapeutics has secured worldwide rights for developing and commercialising VVD-214, the Werner helicase (WRN) ...

Italy’s Axxam and Molecular Health have partnered to identify and validate new therapeutic targets in drug development.

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the ...

Regeneron Pharmaceuticals is to enter an in-licensing agreement with Hansoh Pharmaceuticals to secure exclusive rights for HS ...

MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and with other ...

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights.

The alert comes amid some patients accessing GLP-1RAs through unregulated channels, where safety information is often not ...

A study found no rise in ADHD cases, though some drugs for the disorder are still in shortage amid high demand.